c-Fms

c-Fms-IN-14 (Example 76) is a potent inhibitor of the c-Fms kinase with an IC50 of 4 nM, utilized in cancer and autoimmune disease research [1].

Ataquimast is used in curing advanced receptor-positive breast cancer.

Adrixetinib is an inhibitor of protein tyrosine kinase with antineoplastic activity .

ARRY-382 is a highly selective oral inhibitor of CSF-1R with an IC50 of 9 nM.

JTE-952: oral, selective Type II CSF-1R inhibitor, IC50 = 13 nM for CSF1R, 261 nM for TrkA, effective in mouse arthritis model.

CSF1R-IN-5: Potent CSF1R inhibitor, may alter TAM/glioma inflammatory exchanges, potential cancer research tool. (WO2021197276A1, Compound 11)

Axl/Mer/CSF1R-IN-2 (Comp 4) serves as an inhibitor for Axl, Mer, and CSF1R [1].

SJ-C1044 is an orally effective pan-RAF inhibitor demonstrating immunomodulatory and antitumor activities. It targets wild-type BRAF, wild-type CRAF, and BRAF(V600E) with IC50 values of 331, 257, and 187 nM, respectively. SJ-C1044 suppresses tumor cell proliferation by inhibiting kras activation and MEK-ERK phosphorylation. Additionally, it shows inhibition of VEGFR2, TIE2, and CSF1R, with IC50 values of 100, 23, and 235 nM respectively. The compound enhances the tumor immune microenvironment through inhibition of angiogenesis and modulation of macrophage function. SJ-C1044 is applicable for research in colorectal cancer.

Leustroducsin B is a novel colony-stimulating factor (CSF) inducer extracted from Streptomyces platensis SANK 60191.

GENZ-882706 is a potent colony stimulating factor-1 receptor (CSF-1R) Inhibitor.

Pimicotinib hydrochloride is an inhibitor of CSF1R, displaying antitumor activity.

c-Fms-IN-15 (compound 8g) is a potent inhibitor of FMS kinase, with an IC50 of 563 nM.

Enrupatinib is an inhibitor of the colony stimulating factor 1 receptor (CSF1R), exhibiting antitumor activity.

JNJ-6204 is a deuterated compound that efficiently inhibits CSNK1D and CSNK1E.